JAMA Oncology
LightNews LightNews
banner
jamaoncology.com
JAMA Oncology
@jamaoncology.com
730 followers 59 following 330 posts
JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.

🌐 JAMAOncology.com
Posts Replies Media Videos
jamaoncology.com
A 67-year-old man with a history of λ light-chain multiple myeloma presents with increased serum-free λ light chain levels.

What is your diagnosis? ja.ma/4qJZnu0
The image shows two medical scans. A MIP scan displays a grayscale body outline with pink arrows pointing to specific areas. An axial fused PET/CT scan shows an organ cross-section with colored overlays, highlighting areas marked with pink arrows.
February 14, 2026 at 4:00 PM
jamaoncology.com
Open-source #AI models for #LungCancer EGFR mutation prediction showed high accuracy overall but reduced performance in Asian patients and pleural samples, indicating the need for broader validation.

ja.ma/4kvddi2
Figure 2: Bar plots show model performance across ancestry and specimen sites. Graph A shows DeepGEM and EAGLE model performance for European, American, Asian, and African ancestries. Graph B plots models for lung, lymph node, brain, liver, and other specimen sites.
February 13, 2026 at 3:00 PM
jamaoncology.com
In localized radiorecurrent #ProstateCancer, salvage focal therapy provided similar 10-year survival outcomes as radical prostatectomy but resulted in substantially fewer perioperative complications.

ja.ma/45YvluY
Kaplan-Meier curves show 10-year overall survival. The x-axis represents years since salvage treatment, and the y-axis is overall survival percentage. sFT@1 starts at 100%, decreasing to 57%. sRP@2 begins at 100%, dropping to 72% at 10 years.
February 12, 2026 at 4:30 PM
jamaoncology.com
Individuals diagnosed with cancer in 2020 and 2021 had lower 1-year survival than before the pandemic, with greatest impact seen in older adults and non-Hispanic minority groups.

bit.ly/3OndWG4
Two graphs, "Early-stage cancer diagnosis" and "Late-stage cancer diagnosis", display 1-year cause-specific survival rates from 2015-2021. Early-stage rates are consistently higher with less variance than late-stage rates, which show an upward trend.
February 10, 2026 at 12:00 PM
jamaoncology.com
Individuals diagnosed with cancer in 2020 and 2021 had lower 1-year survival than before the pandemic, with greatest impact seen in older adults and non-Hispanic minority groups.

bit.ly/3ZfiIrF
Figure 1. Changes in 1-Year Cause-Specific Survival (CSS) Rates Among Patients Diagnosed With Cancer in 2020 and 2021. Graph A shows Early-stage cancer diagnosis, while Graph B shows Late-stage cancer diagnosis from 2015 to 2021.
February 8, 2026 at 3:00 PM
jamaoncology.com
Individuals diagnosed with cancer in 2020 and 2021 had lower 1-year survival than before the pandemic, with greatest impact seen in older adults and non-Hispanic minority groups.

bit.ly/4rEzInf
Figure 1 shows 1-Year Cause-Specific Survival rates for cancer patients diagnosed in 2020-2021. Graph A plots early-stage cancer diagnosis, with survival rates rising slightly from 96.3% in 2015 to 96.5% in 2021. Graph B shows late-stage, rising from 72.3% to 75% for the same period.
February 8, 2026 at 2:00 PM
jamaoncology.com
Individuals diagnosed with cancer in 2020 and 2021 had lower 1-year survival than before the pandemic, with greatest impact seen in older adults and non-Hispanic minority groups.

jamanetwork.com/journals/jam...
Two line graphs display cancer survival rates from 2015-2021. Graph A shows 'Early-stage cancer diagnosis,' with a slight increase from 96.3% to 96.5%. Graph B, 'Late-stage cancer diagnosis,' shows a more pronounced rise from 72% to 76%.
February 7, 2026 at 3:00 PM
jamaoncology.com
Individuals diagnosed with cancer in 2020 and 2021 had lower 1-year survival than before the pandemic, with greatest impact seen in older adults and non-Hispanic minority groups.

bit.ly/3O7tgqe
Figure 1: Changes in 1-Year Cause-Specific Survival (CSS) Rates Among Patients Diagnosed With Cancer in 2020 and 2021. A: Early-stage cancer diagnosis shows a slight increase from 96.3% in 2015 to 96.5% in 2021. B: Late-stage cancer diagnosis shows a rise from 72.3% in 2015 to 76.1% in 2021.
February 6, 2026 at 3:00 PM
jamaoncology.com
BrECADD produced better health-related quality of life than escalated BEACOPP in advanced-stage #HodgkinLymphoma, with fewer chemotherapy-related symptoms and improved functioning.

bit.ly/4kg6BnT
Figure 1. CONSORT Flowchart displays patient enrollment in the HD21 trial: 1500 patients enrolled. 424 enrolled outside of Germany, 18 removed. 1058 in the German ITT sample, 53 didn't consent. 1005 randomized, 499 to arm 1, 506 to arm 2.
February 6, 2026 at 2:00 PM
jamaoncology.com
Individuals diagnosed with cancer in 2020 and 2021 had lower 1-year survival than before the pandemic, with greatest impact seen in older adults and non-Hispanic minority groups.

bit.ly/3NUGpDa
Two graphs compare 1-year cause-specific survival rates from 2015-2021. Graph A shows early-stage cancer diagnosis with rates around 96-97%. Graph B shows late-stage diagnosis with a rise from 72% to 76%, but dips in 2020 and 2021.
February 5, 2026 at 4:30 PM
jamaoncology.com
Low-dose aspirin in older adults was not associated with lower #Cancer incidence over 8.6 years, and cancer mortality risk did not persist beyond the exposure period.

ja.ma/4tbKCm1
Graphs show cancer incidence and mortality risk with aspirin; 'A Cancer incidence' depicts lines for Aspirin and Placebo, P=.61. 'B Mortality' shows similar lines, P=.02. Both charts track risk over time since randomization, up to 10 years.
February 3, 2026 at 1:00 PM
jamaoncology.com
This JAMA Oncology Patient Page describes the 3 main types of urinary diversions and care required after surgery to ensure an active and fulfilling life.

ja.ma/4kcLt1v
Diagram illustrating urinary diversion surgery, detailing ileal conduit, orthotopic neobladder, and continent cutaneous pouch options. It includes pros and cons for each procedure, with labeled anatomical structures like the kidney, ureter, bladder, and urethra.
February 3, 2026 at 12:00 PM
jamaoncology.com
The addition of camrelizumab to chemotherapy produced statistically significant and clinically meaningful 5-year OS benefits compared with chemotherapy alone in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.

ja.ma/4rti5Xn
Overall Survival graph shows two lines representing 'Camrelizumab group' and 'Placebo group' over 72 months. The 'Camrelizumab group' shows higher survival rates. Text: HR, 0.74; 95% CI, 0.55-0.99; P = .047. At 60 months, survival rates are 37.8% vs 24.2%.
February 2, 2026 at 3:00 PM
jamaoncology.com
This JAMA Oncology Patient Page describes the 3 main types of urinary diversions and care required after surgery to ensure an active and fulfilling life.

ja.ma/3M9hrPE
Diagram illustrating urinary diversion surgery, detailing ileal conduit, orthotopic neobladder, and continent cutaneous pouch options. It includes pros and cons for each procedure, with labeled anatomical structures like the kidney, ureter, bladder, and urethra.
February 1, 2026 at 11:00 AM
jamaoncology.com
Low-dose aspirin in older adults was not associated with lower #Cancer incidence over 8.6 years, and cancer mortality risk did not persist beyond the exposure period.

ja.ma/45CqTll
Graphs show cancer incidence and mortality risk with aspirin; 'A Cancer incidence' depicts lines for Aspirin and Placebo, P=.61. 'B Mortality' shows similar lines, P=.02. Both charts track risk over time since randomization, up to 10 years.
January 31, 2026 at 3:00 PM
jamaoncology.com
In active surveillance for #ProstateCancer, #MRI was most reliable for ruling out significant cancer in low PSA density cases but failed to achieve sufficient accuracy in broader populations.

ja.ma/4rmlO95
MRI negative predictive values for ruling out grade groups 2 or higher. The y-axis represents negative predictive value, % and x-axis has Overall, White patients, Black patients, GG1 at DBx, GG2 at DBx, PSAD ≥0.15, PSAD <0.15.
January 31, 2026 at 12:00 PM
jamaoncology.com
The addition of camrelizumab to chemotherapy produced statistically significant and clinically meaningful 5-year OS benefits compared with chemotherapy alone in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.

ja.ma/3Z6xe4M
Overall survival graph comparing Camrelizumab to placebo. The y-axis shows "Overall survival, %" from 0 to 100. The x-axis displays "Months" from 0 to 72. HR, 0.74; 95% CI, 0.55-0.99; P = 0.047.
January 30, 2026 at 3:00 PM
jamaoncology.com
In early 2025, the National Cancer Institute terminated 181 extramural grants, totaling more than $640 million in awards. Terminations targeted primarily basic science, general oncology, and early-career investigators.

ja.ma/4k5WUIg
Table titled 'Investigator Rank and Content of Terminated National Cancer Institute Grants'. Lists Investigator rank, Cancer type, Research type and Flagged subjects with number of grants and percentages for each characteristic. N=181.
January 30, 2026 at 12:00 PM
jamaoncology.com
Low-dose aspirin in older adults was not associated with lower #Cancer incidence over 8.6 years, and cancer mortality risk did not persist beyond the exposure period.

ja.ma/3ZC5uoK
JAMA Oncology graphs show cancer incidence/mortality with aspirin. Graph A: Cancer incidence, aspirin vs. placebo, p=.61. Graph B: Mortality, p=.02. Time since randomization is the x-axis. RCT, RCT/post-RCT, and Post-RCT periods are marked.
January 29, 2026 at 4:30 PM
jamaoncology.com
For adults with metastatic HER2-positive #BiliaryTractCancer, zanidatamab led to longer overall survival and reduced pain, supporting its role as a precision therapy option. ja.ma/4rkG6jp
Two charts showing outcomes for biliary tract cancer patients. Top: survival probability over time for IHC 3+, IHC 2+, and overall. Bottom: bar graph of treatment-related adverse events, with diarrhea being the most frequent.
January 29, 2026 at 12:00 PM
jamaoncology.com
Among patients with advanced urothelial cancer, upfront enfortumab vedotin dose reduction was linked to a 50% reduction in treatment interruption risk but did not compromise overall survival. ja.ma/49IUQma
Graphs showing the association of upfront Enfortumab Vedotin (EV) dose reduction with treatment interruption and survival. Graph A shows time to first EV interruption. Graph B shows overall survival for standard and reduced doses.
January 28, 2026 at 12:00 PM
jamaoncology.com
Semaglutide and tirzepatide prescriptions for obesity have increased among patients with preexisting cancer, with notable variation by cancer type and absence of cancer-specific guidelines. ja.ma/45vTlp1
Two line graphs show Semaglutide and Tirzepatide prescription rates among cancer patients, stratified by cancer type. One graph displays overall incident and prevalent prescription rates. The other shows prevalent prescription rate by preexisting cancer type.
January 27, 2026 at 12:00 PM
jamaoncology.com
Cross-disciplinary international position statement summarizes the current understanding of CV toxic effects associated with ICI therapy, including strategies for diagnosis, treatment, and potential rechallenge and an outline of relevant knowledge gaps. ja.ma/46dCKGB
Figure 1 shows the mechanisms of cardiovascular toxic effects with Immune Checkpoint Inhibitor(ICI) Therapies. It illustrates patient risk factors, tumor biology, and immune activation leading to cardiac dysfunction and other CV disorders.
January 26, 2026 at 12:00 PM
jamaoncology.com
In a nonrandomized phase 2 trial of adults with advanced dMMR/MSI-H noncolorectal cancers, combined nivolumab/ipilimumab showed an objective response rate of 63% and 6-month progression-free survival rate of 71%.

ja.ma/4q05XMy
Efficacy Outcomes graph shows tumor change of target lesions. The Y axis indicates the change from baseline, % from 20 to -100. Tumor types include Endometrium and Other. Response, MSI status and MMR IHC are charted.
January 25, 2026 at 3:00 PM
jamaoncology.com
Among women under 50, those with the highest ultraprocessed food intake had 45% higher odds of early-onset colorectal conventional adenomas versus those with the lowest intake; no significant association was seen for serrated lesions. ja.ma/4k1sBmc
Figure 2. Graph showing odds ratio and P for trend of ultraprocessed food intake by subgroups and risk of early-onset colorectal conventional adenoma. P for trend of Sauces, spreads, and condiments is <.01.
January 25, 2026 at 2:00 PM